British Patient Capital
Investor profile
Venture capital
Also recorded as: British PatientCapital
Deals
23
distinct rounds
Companies
19
backed
Active span
2021–2025
5 yrs
Total round €
€1.7B
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Oxford Science Enterprises4
- Cambridge Innovation Capital3
- IQ Capital3
- Northern Gritstone3
- Pfizer Ventures3
- ABN AMRO2
- AlbionVC2
- Andera Partners2
- BGF2
- Canaan Partners2
- Dawn Capital2
- Earlybird Venture Capital2
- Evolution Equity Partners2
- HSBC2
- IP Group2
- Latitude2
- Molten Ventures2
- Parkwalk Advisors2
- Prosperity7 Ventures2
- Warburg Pincus2
- 3B Future Health Fund1
- 83North1
- ABC Impact1
- Advent Life Sciences1
- Aphelion1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Quantexa | UK | 3 | €413M |
| Pragmatic | UK | 2 | €245M |
| Thought Machine | UK | 1 | €178M |
| Quell Therapeutics | UK | 1 | €138M |
| Grey Wolf Therapeutics | UK | 2 | €88M |
| Proximie | UK | 1 | €77M |
| Maxion Therapeutics | UK | 1 | €66M |
| Microbiotica | UK | 1 | €61M |
| Form3 | UK | 1 | €54M |
| Quantum Motion | UK | 1 | €47M |
| Oxford Quantum Circuits | UK | 1 | €45M |
| Phagenesis | UK | 1 | €39M |
| Nucleome Therapeutics | UK | 1 | €38M |
| Epsilogen | UK | 1 | €37M |
| Iceotope | UK | 1 | €35M |
| Accurx | UK | 1 | €32M |
| GaN Devices | UK | 1 | €30M |
| Stream (formerly Wagestream) | UK | 1 | €20M |
| CyberSmart | UK | 1 | €14M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Pragmatic | Series D+ | €212M | 2023-12 |
| Thought Machine | Series C | €178M | 2021-11 |
| Quantexa | Series D+ | €165M | 2025-03 |
| Quell Therapeutics | Series B | €138M | 2021-11 |
| Quantexa | Series D+ | €130M | 2021-07 |
| Quantexa | Series D+ | €118M | 2023-04 |
| Proximie | Series C | €77M | 2022-06 |
| Maxion Therapeutics | Series A | €66M | 2025-03 |
| Microbiotica | Series B | €61M | 2022-03 |
| Form3 | Series C | €54M | 2024-09 |